Author:
Si Xiaojie,Gao Chao,Chi Lingling,Wang Hao,Zhang Yutong,Dai Honglin,Liu Limin,Wang Zhangjie,Zheng Jiaxin,Ke Yu,Liu Hongmin,Zhang Qiurong
Funder
National Natural Science Foundation of China
State Key Laboratory of Geohazard Prevention and Geoenvironment Protection
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics
Reference26 articles.
1. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70:313. https://doi.org/10.3322/caac.21609.
2. Hongyun ZBY. A new classification for targeted anticancer agents. Modern Oncology. 2017;2017, vol. 25, No. 02.
3. Jiang G, Wei F, Yan X, Gao Y, Kong X, Miao S, et al. Research progress on molecular targeted anti-tumor drugs. Anti-tumor Pharmacy. 2016;6. https://doi.org/10.3969/j.issn.2095-1264.2016.03.05.
4. Lu Q, Shui L, Di Z, Chuan L, Fa-jun Z. Study design of early clinical trials and development strategy of targeted anticancer agents approved by FDA. Chin J New Drugs. 2019;2019,28.
5. Bilusic M. What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy? Expert Rev Anticancer Ther. 2022:1–3. https://doi.org/10.1080/14737140.2022.2069097.